11 March 2016 - The EMA has, at the request of the European Commission, started a review of the cancer medicine Zydelig (idelalisib), which is authorised in the EU to treat two types of rare blood cancers, chronic lymphocytic leukaemia and follicular lymphoma.

For more details, go to: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2016/03/news_detail_002487.jsp&mid=WC0b01ac058004d5c1